By: Norma Erickson
06 November 2010
Last Tuesday, the SaneVax team sent a letter to Dr. Margaret Hamburg, FDA Commissioner, and Dr. Harold E. Varmus, Director of the National Cancer Institute (NCI), requesting the establishment of a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care.
To date, American medical consumers must rely on one of two FDA approved HPV tests. One of them generated two to four times the number of positive results as the other, and no one knows which, if either, of the tests are accurate.
The SaneVax team believes American medical consumers have the right to the most reliable testing available. Science has made accurate HPV genotyping available to humanity, but the FDA has not to date approved reliable HPV genotyping for American medical consumers.